HopeStage
Back to all studies
CompletedNCT06965569

Multiple Ascending Dose Phase 1 Study of ALA-3000

This study evaluated the safety and effectiveness of ALA-3000 for people with depression.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of ALA-3000 for people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Little Rock and 3 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: April 21, 2025
Recruitment status
Completed
Enrollment listed in the registry
37
Sponsor
Alar Pharmaceuticals Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT06965569
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of ALA-3000, Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Subjects With Treatment-Resistant Depression (TRD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · St Louis · Eatontown

1 more locations
  • North Canton

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of ALA-3000 for people with depression.

Who is behind this study?

The study sponsor is Alar Pharmaceuticals Inc.

Did this study involve medication?

Yes. The study involved medication, including ALA-3000, Placebo and escitalopram, sertraline, duloxetine or venlafaxine XR.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies